There is an opportunity to extend overall survivalfor patients with advanced liposarcoma2,3
References: 1. Tseng WW, Somaiah N, Lazar AJ, Lev DC, Pollock RE. Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel). 2013;5(2):529-549. 2. HALAVEN [package insert]. Woodcliff Lake, NJ: Eisai Inc; 2017. 3. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629-1637.